Drugs / zigakibart
zigakibart
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05508204 | Jul → Dec 2022 | — | Chinook Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03945318 | Apr 2019 → Jun 2026 | IgA glomerulonephritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT03340883 | Nov 2017 → Jun 2019 | plasma cell myeloma | Chinook Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07146906 | Mar 2026 → Jul 2030 expected | IgA glomerulonephritis | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT06858319 | Jul 2025 → Jun 2031 expected | IgA glomerulonephritis, chronic kidney disease | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT05852938 | Jul 2023 → Aug 2027 expected | IgA glomerulonephritis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04573478 | Dec 2020 → Apr 2028 expected | IgA glomerulonephritis | Novartis Pharmaceuticals | Active not recruiting | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07850752 Background | Dec 2026 → Sep 2028 expected | IgA glomerulonephritis | Novartis Pharmaceuticals | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-11-04 | Novartis Pharmaceuticals | Results New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline novartis.com ↗
Long-Term Stabilization of Kidney Function Regardless of Baseline eGFR and Urine Protein-to-Creatinine Ratio (UPCR) in Patients with IgAN |
| 2025-07-17 | Novartis Pharmaceuticals | Results Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance novartis.com ↗
Updated results from the Phase I/II study for zigakibart in IgAN showed a robust and clinically meaningful reduction in proteinuria of 60.4% from baseline and eGFR stabilization over 100 weeks of treatment. |
| 2024-05-25 | Novartis Pharmaceuticals | Results Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo novartis.com ↗
One Year of Zigakibart Treatment Shows Clinically Meaningful Proteinuria Reduction and Good Tolerability in a Phase 1/2 Study of IgA Nephropathy. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-04 | Novartis Pharmaceuticals | New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline novartis.com ↗ |
| 2025-07-17 | Novartis Pharmaceuticals | Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance novartis.com ↗ |
| 2024-05-25 | Novartis Pharmaceuticals | Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo novartis.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zigakibart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06858319 ↗ |
| Known as | BION-1301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03340883 ↗ |
| Known as | C-90401 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095316 ↗ |
| Action | Inhibit | “durable reductions in levels of free APRIL” PMID 40482854 ↗ Jun 2025 |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody” NCT03340883 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT03945318 ↗ |